ZWS Stock Forecast & Price Target

Zurn Elkay Water Solns is well positioned because its 1Q26 results showed broad-based 11% organic sales growth, an 8% adjusted EBITDA beat, and 160 bps of margin expansion, with commercial and institutional end markets rising 16% and 12% Y/Y, respectively. Its outlook is supported by defensible, specification-driven exposure to nonresidential construction, strong mix in education and healthcare, and a sustainable product portfolio that benefits from replacement demand, regulatory tailwinds, and continued bottle-filler penetration. Financially, the company’s 0.5x net leverage, 61% FCF conversion in the quarter, and 1 million shares repurchased for $50 million provide flexibility for M&A and buybacks while it manages tariffs through supply-chain de-risking and productivity gains.

Zurn Elkay Water Solns is viewed negatively because its growth depends heavily on institutional and commercial construction and remodel activity, which could slow or face deferred budgets in education and healthcare, pressuring demand and share gains. The stock also appears vulnerable to valuation compression if it sustains below-market growth or loses channel/specification share, while execution, supply chain, and commodity volatility in copper, brass, steel, plastics, and electronics could squeeze margins and service levels. Additional downside comes from the risk of overpaying for water M&A and failing to realize expected Elkay cost synergies, with 2027 EPS potentially around $1.71 in a downside case.